| Abstract: |
Natural product-derived heterocyclic compounds represent a cornerstone of modern pharmaceutical chemistry, offering remarkable structural diversity and pharmacological potential. This research investigates the synthetic strategies and pharmacological activities of heterocyclic scaffolds derived from natural sources including alkaloids, flavonoids, coumarins, and terpenoids. The primary objectives include examining contemporary synthetic methodologies such as Pictet-Spengler cyclization, Fischer indole synthesis, and multicomponent reactions for heterocycle construction, alongside evaluating their therapeutic applications. The methodology encompasses comprehensive analysis of published literature from peer-reviewed databases, utilizing comparative analytical approaches to assess pharmacological data. The hypothesis postulates that natural product-derived heterocyclic compounds demonstrate superior bioactivity profiles compared to purely synthetic counterparts due to their evolutionary optimization for biological target interactions. Results reveal that over 85% of FDA-approved drugs contain heterocyclic moieties, with nitrogen-containing heterocycles predominating in anticancer and antimicrobial therapeutics. IC50 values ranging from 0.12 to 16.79 µM were observed across various cancer cell lines for synthesized derivatives. Discussion elaborates structure-activity relationships demonstrating that electron-donating substituents enhance antioxidant potential while specific ring modifications improve target selectivity. In conclusion, natural product-derived heterocycles continue serving as privileged scaffolds for drug discovery, warranting continued exploration of their synthetic accessibility and pharmacological optimization. |
